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Simple Summary: Over the last decade the incidence of enchondroma and atypical cartilaginous
bone tumors (ACTs) increased enormously. Management of these tumors in the long bones is shifting
towards active surveillance, as negative side effects of surgical treatment seem to outweigh the
potential benefits. To support development of evidence-based guidelines for active surveillance,
we studied the natural course of enchondroma and ACTs in the long bones. In this study, MRI
analysis of 128 cases was performed with a minimum interval of 24 months between baseline and
last MRI. Our data showed that the majority of the cartilaginous tumors (87%) remained stable or
showed regression on MRI. Only 13% showed some progression on MRI, although none of the tumors
developed characteristics of high-grade chondrosarcoma. Based on our results, active surveillance
is considered safe for enchondroma and ACTs of the long bones, and follow-up schemes should be
tailored on natural course.
Abstract: Management of atypical cartilaginous tumors (ACTs) in the long bones is shifting towards
active surveillance to avoid unnecessary surgeries. The frequency and duration of active surveillance
for these tumors is unclear as there is little knowledge of its biological behavior. In this retrospective
study, we examined the natural course of enchondroma and ACTs through active surveillance. A
total of 128 central cartilaginous tumors, located in the long bones, with a minimum interval of
24 months between baseline and last MRI were included. MRI characteristics (e.g., size, scalloping, fat
entrapment) were scored and tumors were classified according to the changes between MRIs. Mean
follow-up of this study was 50 months, range = 25–138 months. The majority of the cartilaginous
tumors (87%) remained stable (n = 65) or showed regression (n = 46) on MRI. A total of 87% of the
cases that developed tumor regression presented with entrapped fat at diagnosis. Only 13% (n = 17)
showed some progression on MRI, although none of the tumors developed characteristics of high-
grade chondrosarcoma. Based on our results, active surveillance is considered safe for enchondroma
and ACTs of the long bones. We propose active surveillance for all asymptomatic enchondroma
or ACTs in the long bones irrespective of tumor size, and follow-up schemes should be tailored on
natural course.
Keywords: chondrosarcoma; watchful waiting; magnetic resonance imaging; bone neoplasms
1. Introduction
Nowadays central cartilaginous bone tumors are reported as the most common pri-
mary bone tumor. Enchondroma are benign cartilaginous tumors, whereas chondrosar-
coma are malignant cartilaginous tumors. Chondrosarcomas are divided into grades
Cancers 2021, 13, 4093. https://doi.org/10.3390/cancers13164093 https://www.mdpi.com/journal/cancers
Cancers 2021, 13, 4093 2 of 11
ranging from 1 to 3 which correlate with aggressiveness and; therefore, with local recur-
rence rate, metastatic potential and the disease specific potential. Since chondrosarcoma
grade 1 of the long bones rarely metastasizes and show no signs of local malignant behavior,
the WHO decided in 2013 to change the classification of chondrosarcoma grade 1 (CS1)
from malignant into locally aggressive [1]. In the latest 2020 WHO classification, a clear dis-
tinction between CS1 in the axial skeleton and appendicular skeleton was made [2]. Tumors
in the axial skeleton are still termed CS1, reflecting the more aggressive local behavior and
poorer clinical outcome of tumors at these sites, whereas CS1 in the appendicular skeleton
are now termed atypical cartilaginous tumors (ACTs). Typical for cartilaginous tumors are
the popcorn-like calcifications and the lobulated contours. Due to the numerous similarities
of enchondroma and ACTs on imaging, differentiating these tumors is problematic [3–5].
High-grade chondrosarcoma is recognized by aggressive radiologic features such as bone
destruction and soft tissue extension.
Several studies have shown a rise in incidence of chondrosarcoma over the last
decades, which is mainly caused by ACTs and might be explained by a simultaneous
increase of MRI usage, resulting in more incidental findings [6,7]. Similarly, the incidence
of enchondroma increased over the last decades [6]. Orthopedic oncologists and radi-
ologists are more frequently confronted with the diagnostic dilemma of differentiating
enchondroma and ACT [3–5]. The slight increase in incidence of high-grade chondrosar-
coma (grade 2, 3 and dedifferentiated chondrosarcoma) is much lower than the increase
in incidence of ACTs and enchondroma [6,7]. Based on recent studies on the incidence of
cartilaginous tumors, the risk of transformation of atypical cartilaginous tumors (ACTs)
to high-grade chondrosarcoma (HGCS) is assumed to be <1%, instead of the previously
reported risk of 2.5–6% [6,7].
Due to these new insights, the most recent literature on cartilaginous tumors shifts to-
wards active surveillance for ACTs in the long bones to avoid unnecessary surgeries [8–11].
Several authors have studied active surveillance for central cartilaginous tumors in the
long bones without aggressive imaging characteristics (e.g., cortical destruction, soft tissue
expansion) [12–15]. Omlor et al. showed that active surveillance of enchondroma and
ACTs has benefits in clinical and functional outcomes compared to surgical treatment [15].
However, the frequency and the duration of active surveillance for these tumors is unclear,
as there is little knowledge of their natural course. The few studies that describe the natural
course of enchondroma and ACTs are limited by small numbers of patients and short
follow-up [12,14,16]. Important to mention is that none of these studies described transfor-
mation to HGCS. Overall, active surveillance seems appropriate for central cartilaginous
tumors in the long bones without aggressive characteristics.
The aim of this study is to examine the natural course of central cartilaginous tu-
mors located in the long bones without aggressive imaging characteristics. As magnetic
resonance imaging (MRI) is the imaging method of choice for central cartilaginous tu-
mors [17], we analyzed MRI characteristics of enchondroma and ACTs, in which we
refrained from surgery.
2. Methods
A retrospective cohort study was performed on all patients diagnosed between 2008
and 2017 with central cartilaginous tumors in the long bones without aggressive imaging
characteristics. In total, 391 cartilaginous tumors without aggressive imaging characteristics
were located in the long tubular bones, of which 227 tumors underwent active surveillance
instead of surgical removal (See Figure 1).
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Figure 1. Number of cartilaginous tumors without aggressive characteristics located in the long 
bones treated at our institution between 2008 and 2017. 
For the purpose of this study, patients were included if they met the following crite-
ria: (1) A central cartilaginous tumor located in the long tubular bones, (2) under active 
surveillance, and (3) who underwent at least two MRIs of the tumor with a minimum time 
interval of 24 months. Patients with Ollier’s disease or Maffucci syndrome were excluded. 
Previously biopsied tumors were also excluded as this could interfere with MRI interpre-
tation. 
We did not differentiate between enchondroma and ACT due to the similarities of 
these tumors when located in the long tubular bones [3–5]. After referral to our hospital, 
physical examination was performed and all imaging was reviewed by experienced mus-
culoskeletal radiologists and, if necessary, additional imaging (i.e., X-ray and/or MRI) was 
performed [16]. Active surveillance was advised when neither invalidating pain nor any 
of the following radiological signs of malignancy were seen: cortical destruction, presence 
of soft tissue mass, moth-eaten, permeative or extensive osteolysis, multi-lamellar or ag-
gressive periosteal reaction [16,18,19]. Figure 2 shows an example of an excluded patient 
with radiological signs of malignancy. Patients who accepted the active surveillance were 
followed-up with MRI after 6 months. If MRI showed none of the previously described 
malignant characteristics or excessive tumor growth, active surveillance was continued. 
Patients were educated on their diagnosis and instructed to contact our hospital in case of 
new or increased pain. When invalidating pain or progression of the tumor on MRI (i.e., 
tumor growth, malignant characteristics) occurred, or when the patients revised their 
choice for conservative therapy, patients were surgically treated. Our surgical method 
consists of curettage and cryosurgery, filling of the void with cement or bone graft, and in 
some cases prophylactic plating [20,21]. Curettage material was reviewed by experienced 
pathologists and histological diagnosis was made according to established criteria [1,22]. 
All operated cases were regularly monitored after surgery, consisting of physical exami-
nation and conventional radiology. In cases of clinical or radiological suspicion of local 
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Figure 2. (a,b): Axial CE (contrast enhanced) TSE T1-weighted and axial SE T2-weighted image of 
the proximal humerus of the same patient: Extensive cortical break-through with soft tissue mass in 
a 66-year-old male with histopathologically proven dedifferentiated chondrosarcoma. 
2.1. MRI Analysis 
At our institution all MRIs were performed on a 1.5T scanner, and intravenous gad-
olinium was standardly used. Most patients were referred to our tertiary center with a 
baseline MRI, often performed without gadolinium in the referring hospital. All MRIs an-
alyzed in this study were performed between 2008 and 2020. An experienced senior mus-
culoskeletal radiologist (JdR) scored the following tumor characteristics: craniocaudal 
size, location, presence of endosteal scalloping, peritumoral edema, fat entrapment, ring 
and arc enhancement, calcifications, and replacement of cartilaginous lobules by fatty 
marrow. 
Tumor size was measured as the largest craniocaudal dimension on coronal or sagit-
tal images. To account for possible measurement error, only a size difference of ≥3 mm 
was considered progression or regression. Endosteal scalloping defined as loss of inner 
cortical bone was evaluated on axial images. The degree of scalloping was not quantified, 
scalloping was scored as increased/decreased when there was increased/decreased cir-
cumferential loss of inner cortical bone compared with the baseline MRI. Fat entrapment 
was defined as presence of intralesional foci of high signal intensity on T1-weighted im-
ages, correlating with fat within the cartilage tumor, as described by Vanel et al. [23]. Ring 
and arc enhancement could only be scored when contrast enhanced MRI was available. 
Loss of enhancement might be attributed to increased fat entrapment, increased calcifica-
tion or use of different imaging techniques resulting in different contrast uptake. Fatty 
replacement was only scored on the last MRI and defined as replacement of cartilaginous 
lobules by normal fatty marrow. 
After scoring of the tumor characteristics at baseline and last MRI, tumors were clas-
sified as regression (R), progression (P), or no change (NC). Tumors were classified as 
regression when one or more of the following changes occurred: (1) Decreased tumor size 
(≥3 mm), (2) decreased scalloping, (3) increased calcification, (4) increased fat entrapment 
or (5) replacement of cartilaginous lobules by fatty marrow. Tumors were classified as 
progression when one or more of the following characteristics were scored: (1) Increased 
tumor size (≥3 mm), (2) increased scalloping or (3) loss of calcification. 
2.2. Statistics 
Analysis of the data was performed using IBM SPSS statistics for Windows (version 
25). All continuous variables were visually inspected and tested for normality by the 
Shapiro-Wilk test. 
Figure 2. (a,b): Axial CE (contrast enhanced) TSE T1-weighted and axial SE T2-weighted image of
the proximal humerus of the same patient: Extensive cortical break-through with soft tissue mass in
a 66-year-old male with histopathologically proven dedifferentiated chondrosarcoma.
2.1. MRI Analy is
At our institution a l Is on a 1.5T scan er, and intravenous gadolin-
ium was standar ly used. Most patients were referred to our tertiary center with a baseline
MRI, often perform d without gadolinium i the referring hospital. All MRIs analyzed
in this s udy were performed b tw en 2008 and 2020. An experienced senior muscu-
loskeletal radiologist (JdR) scored the foll wing tumor characteristic : raniocaud l size,
location, presence of ndosteal scal oping, peritumoral edema, fat entrapment, ring and arc
enh nc ment, calcifications, and repl cem nt of cartilaginous obules by fatty marrow.
Tumor size was measured as the largest craniocaudal dimension on coronal or sagittal
images. To account for possible me surement error, only a size difference of ≥3 mm
was considered progression or regression. Endosteal scalloping defin d as loss of inner
cortical bone was evaluated on axial images. The degree of scalloping was not quantified,
scalloping was scored as increased/decreased when there was increased/decreased cir-
cumferential loss of inner cortical bone compared with the baseline MRI. Fat entrapment
was defined as presence of intralesional foci of high signal intensity on T1-weighted i ages,
correlating with fat within the cartilage tumor, as described by Vanel et al. [23]. Ring and
arc enhancement could only be scored when contrast enhanced MRI was available. Loss of
enhancement might be attributed to increased fat entrapment, increased calcification or use
of different imaging techniques resulting in different contrast uptake. Fatty replacement
was only scored on the last MRI and defined as replacement of cartilaginous lobules by
normal fatty marrow.
After scoring of the tumor characteristics at baseline and last MRI, tumors were
classified as regression (R), progression (P), or no change (NC). Tumors were classified as
regression when one or more of the following changes occurred: (1) Decreased tumor size
(≥3 mm), (2) decreased scalloping, (3) increased calcification, (4) increased fat entrapment
or (5) replacement of cartilaginous lobules by fatty marrow. Tumors were classified as
progression when one or more of the following characteristics were scored: (1) Increased
tumor size (≥3 mm), (2) increased scalloping or (3) loss of calcification.
2.2. Statistics
Analysis of the data was performed using IBM SPSS statistics for Windows (version
25). All continuous variables were visually inspected and tested for normality by the
Shapiro-Wilk test.
After MRI analysis, three groups were defined (R, P and NC) and the differences at first
presentation between these groups were assessed. Kruskal–Wallis and Mann–Whitney U
were used for continuous variables. For categorical variables, Chi-squared or Fisher’s exact
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tests depending on expected frequency in cells were used. p-value < 0.05 was considered
statistically significant.
3. Results
In total, 128 tumors in 124 patients (47 male, 77 female) met the inclusion criteria for
this retrospective study. Mean age at diagnosis was 52 years (range 20–76 years). Patient
demographics are reported in Table 1. As our hospital is a tertiary care referral center, 73%
of the cases were first diagnosed in another hospital. Mean time of conservative follow-up
since initial diagnosis is 50 months (range = 25–138 months).
Table 1. Patient demographics.
No Change
(n = 65, 51%)
Regression
(n = 46, 36%)
Progression
(n = 17, 13%) p-Value
Mean age (range, years) 55 (21–73) 52 (23–76) 39 (20–56) 0.000 b, c
Male: Female 25:40 16:30 9:8 0.419
Median follow-up (months) 46 (25–102) 49 (26–116) 47 (30–138) 0.149
Tumor location (n, %) 0.078
Proximal humerus 23 (35.4) 15 (32.6) 3 (17.6)
Humerus diaphysis 0 4 (8.7) 0
Proximal femur 12 (18.5) 4 (8.7) 1 (5.9)
Femur diaphysis 5 (7.7) 7 (15.2) 2 (11.8)
Distal femur 19 (29.2) 13 (28.3) 7 (41.2)
Proximal tibia 2 (3.1) 0 2 (11.8)
Tibia diaphysis 1 (1.5) 1 (2.2) 0
Distal tibia 0 0 1 (5.9)
Proximal fibula 2 (3.1) 2 (4.3) 1 (5.9)
Distal fibula 1 (1.5) 0 0
Baseline MRI characteristics
Median size (mm) 38 (13–158) 54 (14–170) 40 (12–64) 0.000 a, c
Excentric location of the tumor 33 (51) 19 (41.3) 6 (35.3) 0.413
Scalloping 34 (52.3) 20 (43.5) 7 (41.2) 0.557
Fat entrapment 40 (61.5) 40 (87.0) 6 (35.3) 0.000 a, c
Septa nodular enhancement 7 (10.8) 4 (8.7) 4 (23.5) 0.107
Calcifications 57 (87.7) 43 (93.5) 13 (76.5) 0.172
Values are displayed as mean/median (range) or n (%). a = significant difference between NC and R, b = significant
difference between NC and P, c = significant difference between R and P.
3.1. Symptoms at Presentation
The majority of the lesions were incidental findings (125 cases; 97.7%), whereas two
cases (1.6%) were referred with pain that could not be explained by adjacent pathology,
and for one case the referral indication could not be retrieved from the clinical charts.
Most incidental findings (22.4%) were found after patients presented themselves with
knee complaints not related to the tumor (e.g., osteoarthritis, meniscal tears). Some of the
other reasons for imaging were trauma (14.1%), shoulder complaints not related to the
tumor (14.8%), cancer staging imaging studies (8.6%) and rheumatoid arthritis screening
(7.0%). Only two patients (1.6%) reported pain that could not be explained by adjacent
pathology and was; therefore, probably related to the tumor. In both cases pain complaints
were transient and active surveillance was continued. Seven cases developed new pain
complaints during follow-up. In six out of seven cases, physical examination and imaging
showed other causes (e.g., bursitis, osteoarthritis) for the pain. In one case no other cause
was found but the pain was transient and active surveillance was continued.
3.2. MRI Analysis
A total of 65 cases showed no change (NC), 46 regression (R) and 17 progression (P).
MRI characteristics are summarized in Table 2. One case presented with peritumoral edema,
which could be explained by a recent fracture and subsequently diminished on the last MRI.
Of the 46 cases in the regression group, 37 cases showed fatty replacement, 39 increased fat
entrapment, five decreased scalloping, 11 increased calcifications and 17 decrease of tumor
size (mean tumor decrease 8 mm; range 3–30 mm). In the majority of the cases (83%), a
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combination of two or more MRI changes related to regression were seen. Two patients of
the regression group showed tumor growth (3 and 10 mm) prior to development of signs
of regression (increased fat entrapment, fatty replacement). All 17 cases with progression
of the tumor showed increased tumor size over time (median tumor growth 5 mm; range
3–23 mm). Only eight of the 17 cases showed tumor growth over time of more than 5 mm.
Two cases showed loss of ring and arc enhancement in addition to 6 and 23 mm tumor
growth (respectively, 62 and 51 months follow-up). The tumor with 23 mm growth was
removed and histopathologically diagnosed as ACT (Table 3). The other patient remains
under active surveillance as tumor growth developed gradually and the patient has no
pain complaints. None of the cases included in this study showed any aggressive MRI
characteristics often seen in HGCS (e.g., cortical destruction or soft tissue mass extension)
during follow-up.
Table 2. MRI characteristics.
MRI Characteristics











Scalloping 61 (48) 67 (52) - 0 5 (4) 123 (96) -
Peritumoral edema 1 (1) 127 (99) - 0 1 (1) 127 (99) -
Fat entrapment 86 (67) 42 (33) - 39 (30) 0 89 (70) -
Calcifications 113 (88) 15 (12) - 11 (8) 1 (1) 116 (91) -
Ring and arc
enhancement 116 (91) 0 12 0 20 (16) 94 (73) 14
Present Absent
Fatty replacement - - - 37 (29) 91 (71)
N.A.: Not assessable; no contrast enhanced MRI available.
Table 3. Operated cases.

















Incidental 49 Tibia(proximal) 30 5 Growth 40
Sample
error
Incidental * 47 Femur(distal) 50 11 Growth 43 ACT
Incidental 36 Fibula(proximal) 12 4 Growth 49 ACT
Incidental 22 Femur(distal) 34 23
× Growth 55 ACT
Incidental * 38 Tibia(distal) 32 7 Growth 53 ACT
Incidental * 64 Femur(distal) 32 - Prosthesis 57 Enchondroma
* Cases also included in Deckers et al., 2016. × Growth in combination with loss of ring and arc enhancement
on MRI.
In total, six of the 128 cases included in this study were operated (Table 3), either due
to tumor growth (n = 5) or osteoarthritis and total knee arthroplasty was combined with
curettage of the lesion (n = 1). None of the operated cases transformed into HGCS.
4. Discussion
Changes in the WHO classification from chondrosarcoma grade 1 of the long bones
to atypical cartilaginous tumor (ACT), together with the recent insight of low transfor-
mation risk of ACTs (<1%), has resulted in a more conservative treatment approach of
ACTs in literature [1,2,6,7]. Many authors have questioned if the negative side effects of
surgical treatment outweigh the potential benefits and; therefore, proposed active surveil-
lance [6,8,10,12,14–16]. To support development of evidence-based guidelines for active
surveillance, we studied the natural course of enchondroma and ACTs in the long bones. In
this study, MRI analysis of 128 cases was performed with a minimum interval of 24 months
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between baseline and last MRI. The majority of the cartilaginous tumors (87%) remained
stable or showed regression on MRI. Only 13% showed some progression on MRI, although
none of the tumors developed characteristics of high-grade chondrosarcoma (HGCS). Based
on our results, active surveillance is considered safe for enchondroma and ACTs of the
long bones, and follow-up schemes should be tailored on natural course.
Our study provides additional evidence that cartilaginous tumors located in the long
bones can be regressive. In the present study, 46 cases (36%) developed signs of regression
during follow-up (52 months, range 26–116). In line with Chung et al., we showed a
larger incidence of regression than progression during follow-up [12]. Replacement of
cartilaginous lobules by normal marrow fat is only mentioned in a few studies, as most
studies focus on tumor size, scalloping and development of aggressive features [12,24]. This
fatty replacement was seen in 29% of our cases, predominantly in peripheral areas of the
tumor (Figures 3 and 4). Sensarma et al. proposed that a process similar to endochondral
ossification might explain resorption of cartilage lesions [24]. Entrapped fat was present at
diagnosis in majority (87%) of cases that underwent regression and might predict biological
behavior. Entrapped fat is known as a reliable MRI characteristic to differentiate benign
from malignant tumors [18,19,23,25]. A combination with fatty replacement was seen in 36
of the 90 cases (40%) that either presented with fat entrapment at diagnosis or developed
fat entrapment during follow-up. None of the cases in this study showed a decrease of
fat entrapment during follow-up. In those six cases of the progression group in which
entrapped fat was seen at diagnosis, only minimal growth was reported (median 3.0 mm).
Since two cases also showed tumor growth followed by signs of regression, including fat
entrapment, we hypothesize that cases with entrapped fat in the progression group might
develop signs of regression later on.





Figure 3. (a,b): Coronal Spin Echo T1 weighted images of the same cartilaginous tumor three years 
apart. Signs of fatty replacement are seen peripheral and central in the tumor. 
  
(a) (b) 
Figure 4. (a,b): Coronal Spin Echo T1 weighted images of the same cartilaginous tumor four years 
apart. Almost complete replacement of the cartilaginous tumor by normal bone marrow fat. 
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Cancers 2021, 13, 4093 8 of 11





Figure 3. (a,b): Coronal Spin Echo T1 weighted images of the same cartilaginous tumor three years 
apart. Signs of fatty replacement are seen peripheral and central in the tumor. 
  
(a) (b) 
Figure 4. (a,b): Coronal Spin Echo T1 weighted images of the same cartilaginous tumor four years 
apart. Almost complete replacement of the cartilaginous tumor by normal bone marrow fat. 
Figure 4. (a,b): Coronal Spin Echo T1 eighted i ages of the sa e cartilaginous tu or four years
apart. Almost complete replacement of the cartilaginous tumor by nor al bone arro fat.
All cases that were scored as progressive (n = 17; 13%) showed tumor growth, but
only in eight cases (6%) tumor growth over 5 mm was seen. The clinical relevance of
including cases in the progression group with tumor growth ≤5 mm measured over our
midterm follow-up period could be questioned. Although five cases were operated due to
tumor growth, surgery could have been redundant to achieve oncological safety, because
none showed histopathological signs of HGCS. Besides, it is important to note that tumor
progression in this study was seen in relatively small tumors (size at diagnosis ranged from
12 to 64 mm). Cartilage tumors in the long bones smaller than 5 cm are often considered to
behave benign and are; therefore, discharged from follow-up in some institutions [26,27].
Based on our findings of tumor growth mainly occurring in relatively small tumors, we
would recommend active surveillance irrespective of tumor size. Although patients in the
progression group were significantly younger (Table 1), we felt we could not conclude that
progression is only seen at young age due to the wide range (20–56 years). Our finding
implies that older patients (e.g., >65 years old) might not need frequent follow-up. Future
studies are needed to investigate if active surveillance should be tailored to age difference.
Previous studies have suggested scalloping to be a distinctive feature to differentiate
between enchondroma and ACT [18,28]. The results from this study have shown that
presence of scalloping does not predict natural course as scalloping was reported in all
three groups and there was no significant difference between these groups (Table 1). The
clinical relevance of measuring scalloping could be questioned as there is also only fair
observer agreement [3,29].
Active surveillance for ACTs prevents unnecessary surgery and should be the treat-
ment of choice for asymptomatic cartilaginous tumors in the long bones. Due to sparse
knowledge on the biological behavior of these tumors, guidelines for active surveillance
are lacking and follow-up strategies vary amongst institutions. The Birmingham study
group developed a pragmatic imaging tool for triaging cases for referral [11]. We agree
that the current rise in incidence of these tumors warrants a pragmatic approach, as a
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large prospective long term follow-up study would take too long to accomplish. Since we
concluded that these tumors show both progression and regression, we propose tumor
follow-up schemes should be tailored accordingly.
For active surveillance, we propose an MRI follow-up six months after diagnosis. If
HGCS were mistakenly treated with active surveillance, radiologic change of HGCS would
be expected within six months. In the study of Davies et al., only two out of 97 patients,
with two or more MRI examinations, were diagnosed with HGCS showing malignant
characteristics after five and seven months on MRI follow-up [13]. Furthermore, a six-
month follow-up would support patients’ wellbeing, since anxiety may arise after the initial
diagnosis, which is relieved after a follow-up MRI that shows a stable or regressed tumor.
The next steps in active surveillance are dependent on changes in tumor characteristics
at the first follow-up MRI, six months after diagnosis. When the first follow-up shows no
changes, a biennial MRI is recommended. This follow-up period might even be extended
when the tumor remains stable after longer follow-up. When tumors show regression in
asymptomatic patients, we would advise a follow-up MRI at three years after first signs of
regression. If the three-year MRI shows no change or continued regression, the patient can
be discharged with instructions to contact the hospital in case of new or increased pain.
Due to the still limited follow-up of this study, we currently discourage discharge of the
patient when first signs of regression are seen. When tumors show progression during
follow-up without development of malignant characteristics (e.g., cortical destruction, soft
tissue extension), next follow-up MRI is recommended within one year. When tumor
growth is accompanied with persistent pain related to the tumor, intralesional surgery
is advised.
Although active surveillance seems effective for ACTs in the long bones, we should be
cautious for active surveillance to become a cycle of never ending follow-up and prevent
overutilization of costly advanced imaging. Therefore, long-term follow-up studies are
necessary and predictive nomograms should be developed. Furthermore, future studies
should not only focus on aggressive characteristics (e.g., tumor growth, scalloping) but
also on characteristics that might predict regression. Based on this study, fat entrapment at
diagnosis seems a promising MRI characteristic to predict tumor regression.
This study is limited by its retrospective design, because the indication for surgery
changed during the study period. Whereas cases with minimal tumor growth were oper-
ated at the start of the study, we currently refrain from surgery. Furthermore, the exact
number of enchondroma and ACTs in this active surveillance study is not known as there
was no clinical benefit for majority of the patients to perform biopsy or intralesional surgery.
5. Conclusions
In conclusion, the natural course of cartilaginous tumors can either show progression,
stability or regression. This study shows that active surveillance for enchondroma and
ACTs in the long bones is safe, as none of the included tumors developed aggressive
characteristics. Follow-up schemes should be tailored according to biological behavior to
prevent overutilization of costly advanced imaging.
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